Quarterly ResultJul 23, 2026, 08:27 AM
argenx Q2 Product Sales $1.5B, H1 $2.8B; VYVGART Label Expanded
AI Summary
argenx SE reported strong financial results for the second quarter and half-year 2026, driven by robust sales of VYVGART. Global product net sales for Q2 reached $1.5 billion, marking a 60% year-over-year growth, while half-year sales hit $2.8 billion. The company successfully launched VYVGART and VYVGART Hytrulo for all generalized myasthenia gravis (gMG) serotypes, significantly expanding its market opportunity. Key pipeline milestones are also on track, with registrational study readouts for autoimmune myositis expected in Q3 2026 and for multifocal motor neuropathy (MMN) in Q4 2026.
Key Highlights
- Q2 2026 global product net sales reached $1.5 billion, a 60% year-over-year increase.
- Half-year 2026 global product net sales were $2.8 billion, up $1.1 billion from H1 2025.
- Q2 2026 operating profit was $494 million, a 146% increase year-over-year.
- Basic profit per share for Q2 2026 was $7.58, up from $4.02 in Q2 2025.
- VYVGART and VYVGART Hytrulo launched for all gMG serotypes, expanding patient reach.
- Cash, cash equivalents, and current financial assets totaled $5.2 billion as of June 30, 2026.
- Registrational autoimmune myositis study readout is on track for Q3 2026.
- Registrational MMN study readout for empasiprubart is on track for Q4 2026.
Price Impact
More from ARGX